Hormonal
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular mortality, overall mortality, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.
If you have type 2 diabetes and existing heart disease, SGLT2 inhibitors (like empagliflozin, dapagliflozin, or canagliflozin) are now recommended not just for blood sugar, but to significantly lower your risk of heart failure, heart attack, stroke, and death. This benefit exists even if your blood sugar control doesn't change much, suggesting the drug protects your heart and kidneys directly.
EMPA-REG OUTCOME trial in patients with type 2 diabetes (T2D) and established cardiovascular disease randomized to empagliflozin versus placebo reported a 14% reduction in the primary composite outcome of CV death, nonfatal myocardial infarction, nonfatal stroke, and >30% reductions in cardiovascular mortality, overall mortality and heart failure hospitalizations associated with empagliflozin – even though by design, the HbA1c difference between the randomized groups was marginal.
Why this rating
Based on the EMPA-REG OUTCOME trial, a large-scale, randomized, controlled clinical trial.
Source
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
Hiddo J.L. Heerspink et al. · Circulation · 2016
DOI 10.1161/circulationaha.116.021887
More from this paper
- SGLT2 inhibitors lower blood pressure by approximately 4-6 mmHg systolic and 1-2 mmHg diastolic, primarily through plasma volume contraction and reduced arterial stiffness.Good
- SGLT2 inhibitors cause an acute, dose-dependent reduction in eGFR (~5 ml/min/1.73m2) and a ~30-40% reduction in albuminuria, which are protective renal hemodynamic effects rather than signs of kidney damage.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →